Stock solutions were prepared and dissolved following manufacturers instructions
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
Peptide & Gentle Vitamin C Complex: Formulated with Peptide and a gentle Vitamin C derivative to help support softer, smoother, healthier-looking lips
*Correspondence: Baraa K
Using a smaller volume syringe (e.g., 0.3mL or 0.5mL) can make it easier to accurately measure smaller doses, as the unit markings are spaced further apart
These links are still under investigation, but patients should be advised to report any sudden vision changes